Prelude Therapeutics
PRLDPrelude Therapeutics is a clinical-stage precision oncology company focused on discovering and developing novel small molecule therapies for underserved cancer patients.
Table of contents
Earnings
Next report
Aug 13, 2026 (in a month)Competitors
By market cap
By revenue growth
Profile
Prelude Therapeutics is a clinical-stage precision oncology company focused on discovering and developing novel small molecule therapies for underserved cancer patients. The company leverages a proprietary drug discovery engine combining cancer biology and medicinal chemistry to target oncogenic driver pathways. Its pipeline includes diverse therapeutic modalities such as kinases, targeted protein degraders, and precision antibody-drug conjugates.
A clinical-stage biotechnology firm utilizing a specialized discovery engine to develop first-in-class or best-in-class precision medicines, often through strategic collaborations with larger pharmaceutical entities.
Questions, answered.
- What is Prelude Therapeutics's market cap?
- Prelude Therapeutics (PRLD) has a market capitalization of $391.1M and trades on NASDAQ.
- Who are Prelude Therapeutics's competitors?
- Prelude Therapeutics's key competitors include Olema Oncology, Ideaya Biosciences, Pfizer Inc., and others. These companies compete in similar markets and product categories.
- Who does Prelude Therapeutics partner with?
- Prelude Therapeutics's notable partners include AbCellera Biologics, Inc., Incyte Corporation.
- Where is Prelude Therapeutics headquartered?
- Prelude Therapeutics is headquartered in United States of America and employs approximately 128 people. It has been publicly traded since 2020.